Abstract Library

#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,

#2796 Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey

Introduction: Merkel cell carcinoma (MCC) is a rare, tumor of the skin associated with high recurrence rates and poor survival. Clinical trials have shown activity of checkpoint inhibitors targeting programmed death-(ligand)-1 (PD-(L)1). Avelumab is the only PD-L1 inhibitor that has been approved in the Netherlands for advanced/metastatic MCC (mMCC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Levy S

Authors: Levy S, Aarts M, Eskens F, Keymeulen K, Been L,

Keywords: Merkel Cell Carcinoma, Avelumab, PD-L1,

#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Vyakaranam A

Authors: Vyakaranam A, Crona J, Thiis-Evensen E, Hellman P, Norlén O,

Keywords: PRRT, 177Lu-DOTATATE, Pheochromocytoma, Paraganglioma,

#2774 Metastatic Merkel Cell Carcinoma Associated Paraneoplastic Hyponatraemia: Response to Avelumab

Introduction: Merkel cell carcinoma (MCC) is rare, encompassing primary cutaneous neuroendocrine carcinoma.It has an aggressive natural history, and exhibits high response rates to radiotherapy & chemotherapy but often of short duration.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Demirel S

Authors: Saunders E, Demirel S, Kim S, Skelly R, Mukesh M,

Keywords: merkel cell carcinoma, paraneoplastic syndrome, hyponatraemia,

#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)

Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Braat A

Authors: Braat A, Rutger B, Van Rooij R, Braat M, Wessels F,

Keywords: NET, PRRT, SIRT, Radioembolization, Ho-166, Neuroendocrine tumor,